Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Abiraterone acetate

Nature Reviews Drug Discovery volume 10, pages 573–574 (2011)Cite this article

Subjects

Abstract

In April 2011, abiraterone acetate (Zytiga; Centocor Ortho Biotech), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structure of abiraterone acetate.

References

  1. Jemal, A. et al. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).

    Article  Google Scholar 

  2. Attard, G., Belldegrun, A. S. & de Bono, J. S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241–1246 (2005).

    Article  Google Scholar 

  3. Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867–3875 (2011).

    Article  CAS  Google Scholar 

  4. Potter, G. A. et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17, 20-lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463–2471 (1995).

    Article  CAS  Google Scholar 

  5. US Food and Drug Administration. FDA labeling information — Zytiga. FDA website [online], (2011).

  6. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  Google Scholar 

  7. Efstathiou, E, & Logothetis, C. J. A new therapy paradigm for prostate cancer founded on clinical observations. Clin. Cancer Res. 16, 1100–1107 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Christopher J. Logothetis and Eleni Efstathiou are at the Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA.,

    Christopher J. Logothetis & Eleni Efstathiou

  2. Fil Manuguid is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Fil Manuguid

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.,

    Peter Kirkpatrick

Authors
  1. Christopher J. Logothetis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eleni Efstathiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fil Manuguid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

Christopher J. Logothetis has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.

Eleni Efstathiou has received research support from Johnson & Johnson, Bristol-Myers Squibb and Medivation, and honoraria from Johnson & Johnson and Bristol-Myers Squibb.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Logothetis, C., Efstathiou, E., Manuguid, F. et al. Abiraterone acetate. Nat Rev Drug Discov 10, 573–574 (2011). https://doi.org/10.1038/nrd3516

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3516

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research